Pancreas · 2025
Circulating Biomarkers of Macrophage Activation in Different Stages of Chronic Pancreatitis: A Pilot Study.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hagn-Meincke Rasmus, Novovic Srdan, Hadi Amer, Jensen Annette B, Drewes Asbjørn M, Krarup Henrik, Frøkjær Jens B, Park Walter G, Jørgensen Peter L, Møller Holger Jon, Deleuran Bent W, Olesen Søren S
Аннотация
OBJECTIVES: Activation of type M2 macrophages has been implicated in the pathogenesis of chronic pancreatitis (CP). In a clinical pilot study, we investigated blood-based markers of macrophage activation at different stages of CP.
MATERIALS AND METHODS: We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC).
RESULTS: In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 ( P = 0.019) and sCD206 ( P = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP ( P = 0.042) compared to suspected CP. ROC analysis revealed the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/mL (AUC-ROC 0.65; 95% confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/mL (AUC-ROC 0.66; 95% CI, 0.54-0.78). MCP-1 concentrations showed no differences across subgroups.
CONCLUSION: Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.
MATERIALS AND METHODS: We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC).
RESULTS: In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 ( P = 0.019) and sCD206 ( P = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP ( P = 0.042) compared to suspected CP. ROC analysis revealed the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/mL (AUC-ROC 0.65; 95% confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/mL (AUC-ROC 0.66; 95% CI, 0.54-0.78). MCP-1 concentrations showed no differences across subgroups.
CONCLUSION: Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.
Предметные рубрики MeSH
HumansPilot ProjectsMaleFemaleBiomarkersPancreatitis, ChronicMiddle AgedReceptors, Cell SurfaceMacrophage ActivationAntigens, CDCross-Sectional StudiesCD163 AntigenLectins, C-TypeAntigens, Differentiation, MyelomonocyticAdultChemokine CCL2Mannose-Binding LectinsROC CurveMacrophagesMannose ReceptorProspective StudiesAgedCase-Control Studies